Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]
Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.
Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.
5 Rheumatology Headlines You Missed in December 2025
Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation
1.
Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma
2.
Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.
3.
New research uncovers link between cancer pathway and blood-retina barrier function
4.
Lung cancer screening adherence rates decline annually after baseline screening
5.
Chromatin organization linked to p53 tumor suppression mechanism
1.
The Latest Research on Wiskott Aldrich Syndrome
2.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
3.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
4.
Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape
5.
Uncovering the Mystery of Burkitt's Lymphoma: A New Hope for Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
3.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
4.
Efficient Management of First line ALK-rearranged NSCLC - Part V
5.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge